Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | SVP, CFO & Treasurer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 411,380 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Sale · Disposed 42,442 · Balance 411,380 F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy Wife | 635 |
Reported balance
Holding disclosure · report date 2026-03-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 635 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 18:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 42,442 | $8.27 | $350,821.33 |
DisclosureSEC source: 0001806596-26-000002 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,380 F1 · shares: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 17:48 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-059778 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,822 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2027, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 16:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Tax withholdingCommon Stock | 26,941 | $4.76 | $128,239.16 |
DisclosureSEC source: 0000950170-25-032273 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,822 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 19:04 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | PurchaseCommon Stock | 2,000 | $4.39 | $8,778.80 |
DisclosureSEC source: 0000950170-25-025914 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,763 Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 19:44 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024487 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,763 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2026, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| July 29, 2024 Filed Jul 29, 2024 17:24 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 2,251 | $5.92 | $13,326.60 |
DisclosureSEC source: 0000950170-24-087381 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,763 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. Read SEC document |
| March 05, 2024 Filed Mar 6, 2024 16:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,902 | $4.20 | $37,410.66 |
DisclosureSEC source: 0000950170-24-027253 · ownership.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,014 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.195 to $4.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:46 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,798 | $4.48 | $25,982.00 |
DisclosureSEC source: 0000950170-24-027253 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,916 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.435 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 16:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-018027 · ownership.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,714 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2025, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 1,800 | $6.31 | $11,349.00 |
DisclosureSEC source: 0001209191-23-043990 · doc4.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,714 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 16:30 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 412 | $6.30 | $2,595.60 |
DisclosureSEC source: 0001209191-23-043990 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,514 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 16:34 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 16,000 | $6.29 | $100,710.40 |
DisclosureSEC source: 0001209191-23-038417 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,926 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.23 to $6.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 18:25 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,968 | $6.28 | $37,498.73 |
DisclosureSEC source: 0001209191-23-016461 · doc4.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,926 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2455 to $6.3001, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:25 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,966 | $6.26 | $49,845.65 |
DisclosureSEC source: 0001209191-23-016461 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,894 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.2721, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:09 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-23-011340 · doc4.xml · derivative · entry 3 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2033-02-15 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 18:09 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011340 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,860 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 17:56 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001209191-22-060225 · doc4.xml · derivative · entry 4 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2022-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option fully vested and exercisable. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 17:56 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 4,792 | $10.61 | $50,826.83 |
DisclosureSEC source: 0001209191-22-060225 · doc4.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,160 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $10.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 17:56 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 7,500 | $3.12 | $23,400.00 |
DisclosureSEC source: 0001209191-22-060225 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 16:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 2,239 | $10.97 | $24,561.83 |
DisclosureSEC source: 0001209191-22-043682 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,452 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| March 02, 2022 Filed Mar 2, 2022 21:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 8,832 | $11.28 | $99,649.69 |
DisclosureSEC source: 0001209191-22-015155 · doc4.xml · nonDerivative · entry 3 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,691 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.18 to $11.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 21:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,473 | $11.19 | $38,862.87 |
DisclosureSEC source: 0001209191-22-015155 · doc4.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,523 F2 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $11.36 | $0.00 |
DisclosureSEC source: 0001209191-22-015155 · doc4.xml · derivative · entry 5 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2032-02-27 F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:27 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015155 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,996 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 09:15 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 2,130 | $19.24 | $40,972.89 |
DisclosureSEC source: 0001209191-21-048738 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,296 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.22 to $19.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 18:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 6,044 | $18.23 | $110,190.58 |
DisclosureSEC source: 0001209191-21-017274 · doc4.xml · nonDerivative · entry 2 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,426 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,327 | $18.57 | $61,780.06 |
DisclosureSEC source: 0001209191-21-017274 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,470 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.55 to $18.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $20.28 | $0.00 |
DisclosureSEC source: 0001209191-21-014876 · doc4.xml · derivative · entry 3 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2031-02-23 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 17:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 32,700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-014876 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,797 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001209191-20-043999 · doc4.xml · derivative · entry 3 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-07-26 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on July 27, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 17,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043999 · doc4.xml · nonDerivative · entry 1 Moran Kevin Patrick · CIK 0001806596 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,097 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on July 27, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.